ReviewCold Spring Harbor perspectives in medicine2014
Clinical immunology and multiplex biomarkers of human tuberculosis.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.Annals of medicine · 2020Pooled it
- The meta-analysis for ideal cytokines to distinguish the latent and active TB infection.BMC pulmonary medicine · 2020Pooled it
- Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.Frontiers in cellular and infection microbiology · 2021Trial
- Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.PloS one · 2016Trial
- Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles From Asymptomatic Tuberculosis Patients.The Journal of infectious diseases · 2026Article
- Peripheral blood neutrophil proteomic profiling with transcriptomic data integration reveals biomarkers for tuberculosis infection diagnosis.EBioMedicine · 2025Article
- COVID-19 and Tuberculosis: Mathematical Modeling of Infection Spread Taking into Account Reduced Screening.Diagnostics (Basel, Switzerland) · 2024Article
- Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care.Diagnostics (Basel, Switzerland) · 2021Review
- Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis.The Journal of infectious diseases · 2020Article
- A three-marker protein biosignature distinguishes tuberculosis from other respiratory diseases in Gambian children.EBioMedicine · 2020Article
- Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.Frontiers in immunology · 2020Article
- Design and Construction of a Eukaryotic Cloning Vector Encoding the mpt51 Gene ofReports of biochemistry & molecular biology · 2019Article
- Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.Clinical microbiology reviews · 2018Review
- Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB.Journal of translational medicine · 2018Article
- Proteomics ofFrontiers in immunology · 2018Review
- Article
- [Drug-resistant tuberculosis. Epidemiology, diagnostics and therapy].Der Internist · 2016Review
- Interleukin-10 Family and Tuberculosis: An Old Story Renewed.International journal of biological sciences · 2016Review
- Review
- Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals.EBioMedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of tuberculosis (TB) biomarkers is an important goal in current TB research, because the availability of such markers would have significant impact on TB prevention and treatment. Correlates of protection would greatly facilitate vaccine development and evaluation, whereas correlates of TB disease risk would facilitate early diagnosis and help installing early or preventive treatment. Currently, no such markers are available. This review describes several strategies that are currently being pursued to identify TB biomarkers and places these in a clinical context. The approaches discussed include both targeted and untargeted hypothesis-free strategies. Among the first are the measurements of specific biomarkers in antigen-stimulated peripheral blood, in serum or plasma, and detailed immune cell phenotyping. Among the latter are proteomic, genomic, and transcriptomic (mRNA, miRNA) approaches. Recent and promising developments are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.